IMEIK Technology Development Co.

What IMEIK Technology Development Co. does

IMEIK Technology Development Co. (爱美客技术发展股份有限公司) is a Beijing-headquartered biomedical company that develops, manufactures, and commercializes injectable soft tissue repair materials for the Chinese medical aesthetics market. Its product portfolio centers on hyaluronic acid sodium dermal fillers sold under multiple brands (爱芙莱/Aifulai, 宝尼达/Baonida, 逸美/Yimei, 逸美一加一/Yimei 1+1, 嗨体/HEARTY) and absorbable facial thread lift products, with the newer Angel Series (濡白天使, 如生熊猫, 惟她天使) extending into premium indications. The company also operates HEARTY as a medical-grade skincare brand bridging clinical and consumer channels.

Underlying the product line are five proprietary manufacturing technologies: multi-component composite matrix hydrogel, solid-state gradient interpenetrating crosslinking, water-dense microsphere suspension preparation, tissue fluid biomimetic, and precision water-accurate cutting. IMEIK is a National High-Tech Enterprise and operates the Beijing Engineering Laboratory for Biodegradable New Materials, with the company leading participation in national science programs in these areas.

The company makes money through one-time B2B sales of medical devices to hospitals, medical aesthetic clinics, and licensed plastic surgery centers via direct sales and an authorized distributor network. Pricing is not publicly disclosed and is negotiated per transaction. Demand is supported by a credentialed practitioner ecosystem - the 全轩学苑 (Quanxuan Academy) has trained over 7,000 doctors - and by a serialized product authentication system that ties supply chain integrity to authorized doctors and distributors. Operations are concentrated entirely in mainland China.

Name

IMEIK Technology Development Co.

Legal name

爱美客技术发展股份有限公司 (IMEIK Technology Development Co., Ltd.)

Website

https://imeik.com

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

501–1,000 employees

Short description

IMEIK Technology Development is a Beijing-based biomedical company that develops and commercializes hyaluronic acid dermal fillers, absorbable facial thread lifts, and medical-grade skincare for the Chinese medical aesthetics market, selling through B2B channels to hospitals and clinics.

Ownership category

akta.pro rank

Product category

Medical Aesthetic Dermal Fillers

NAICS

Surgical Appliance and Supplies Manufacturing (339113), Medical Equipment and Supplies Manufacturing (3391)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Cosmetic Dermatology (Aesthetic Injectables) (HLAKACAE)

akta.pro secondary industry

Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG)

Keywords

• Dermal filler products
• Hyaluronic acid injections
• Medical aesthetic devices
• Soft tissue repair
• Facial thread lifts

Headquarters

HQ city

Beijing

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales

Revenue model

1. Medical Aesthetic Dermal Fillers and Implants: IMEIK generates revenue primarily from the sale of biomedical soft tissue repair materials, including hyaluronic acid dermal fillers and facial埋植线 (facial implant threads). These are one-time purchase medical devices sold to hospitals and aesthetic clinics.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

IMEIK Technology Development Co. (爱美客技术发展股份有限公司) researches, develops, manufactures, and sells biomedical soft tissue repair materials for the medical aesthetics industry in China. Its core offerings are hyaluronic acid sodium dermal filler products and absorbable facial implant threads for facial contouring, wrinkle reduction, soft tissue augmentation, and minimally invasive thread-lift procedures, supplemented by a medical-grade skincare line and a doctor training platform.

Product overview

IMEIK Technology Development Co. is a platform company specializing in bio-medical soft tissue repair materials R&D and industrialization. The company offers a portfolio of hyaluronic acid sodium filler products (爱芙莱, 嗨体, 宝尼达, 逸美, 逸美一加一) and facial thread lift products. Additional product lines include the Angel Series (濡白天使, 如生熊猫, 惟她天使) and 嗗科拉 brand. The product platform serves the medical aesthetics field, providing compliant pre-operative, intra-operative, and post-operative solutions for aesthetic treatments. The company also operates HEARTY·嗨体 as a medical-grade skincare brand for skin management, and 全轩学苑 as an educational platform for training medical aesthetic doctors.

Differentiator

Problem solved

Functional benefit

Brands

• 爱芙莱 (Aifule): Hyaluronic acid filler product brand
• 嗨体 (HEARTY)
• 宝尼达 (Baonida)
• 逸美 (Yimei)
• 逸美一加一 (Yimei 1+1)
• 濡白天使 (Rugubaitianshi)
• 如生熊猫 (Rushengxiongmao)
• 惟她天使 (Weitaianshi)
• 嗗科拉 (Gukela)
• 全轩学苑 (Quanxuan Academy)

Products and services

• 爱芙莱 (Aifulai)

Quantifiable outcome

• Over 7,000 doctors trained through the 全轩学苑 platform

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• Authorized Partner DoctorscoreChannel Partner/ Reseller/ DistributorLicensed medical doctors and aesthetic practitioners who are authorized to use IMEIK products in clinical settings. IMEIK provides a brand cooperation doctor lookup system, allowing patients to verify the authorization status of individual practitioners. These partners form the primary delivery channel for IMEIK's medical aesthetic products.

Scale indicators1 record

Recent moves6 records

Expansion highlights5 records

Direct peers

• Galderma: Global leader in dermatology and aesthetic injectables (Restylane, Sculptra). Direct competitor to IMEIK's hyaluronic acid fillers and emerging biostimulator categories; both serve medical aesthetic clinics with injectable soft-tissue products.
• Merz Aesthetics: Markets Belotero fillers, Radiesse biostimulators, and Ultherapy. Direct competitor in soft-tissue fillers and the regenerative/biostimulator space where IMEIK's Angel series and microsphere technology compete.
• Bloomage Biotechnology: Leading Chinese HA-based biotech with both medical aesthetics (dermal fillers under 润致 brand) and consumer skincare lines. Closest domestic peer; competes directly in Chinese HA filler market.
• Hyron Biomedical: Chinese developer of cross-linked HA fillers and aesthetic injectables. Direct domestic peer competing in the Chinese HA filler regulatory and distribution landscape.
• Wuhan Yicheng Biological Products: Chinese biotech producing hyaluronic acid-based medical products and aesthetic injectables. Domestic peer in the same regulatory and clinical channel landscape.

Regional players

• LG Chem (LG Life Sciences): South Korean chemical/life sciences conglomerate with aesthetic filler (Yvoire) and skincare portfolios. Regional player with comparable HA filler technology targeting Asian markets where IMEIK competes.

Broad incumbents

• Huadong Medicine: Chinese pharma with growing aesthetics franchise (acquired Sinclair's Ellansé and MaiLi HA fillers). Competes with IMEIK in Chinese medical aesthetics and is a major distribution/incumbent player.
• AbbVie (Allergan Aesthetics): Owner of the Juvéderm filler franchise and Botox. Competes with IMEIK in HA dermal fillers and adjacent facial aesthetics; broader portfolio across biologics and devices.

Emerging players

• Sinclair Pharma (acquired by Huadong): European aesthetics company focused on collagen-stimulator (Ellansé) and HA filler products. Now under Huadong; competes with IMEIK's regenerative filler and Angel series products.
• Teoxane Laboratories: Swiss-based HA filler specialist (Teosyal range). Competes in premium HA dermal fillers and is expanding into Chinese and Asian markets overlapping with IMEIK.

Market position

Strengths1 record

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights1 record

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments4 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IMEIK Technology Development Co.